>fig|379.118.peg.5436 NAD(P)H oxidoreductase YRKL (EC 1.6.99.-) @ Putative NADPH-quinone reductase (modulator of drug activity B) @ Flavodoxin 2
ATGAGAGTTCTCGTCCTTCACTCGCATCCGGTCGAGGAAAGCTACGGCAAGGCGCTTTACAACCAGACGCTGGAAAGCCTTCGCAAAGCCGGTCACGAGGTGGATGCCTGCGATCTCTATGCCGAGGAATTCGATCCCGTTCTCTCACGCCACGACCGGCTCGCCTATCACCACTATCCCGGCAATACCGCGCTGGTGAAGCCCTATGTCGATCGGCTGAAACAGGCCGAAGGGCTGGTGCTGGTGACGCCTGTCTGGAATTTTGGGTTCCCGGCAATCCTCAAAGGCTATTTCGATCGCGTCTGGCTCCCGGGCGTCTCTTTTGAACTTGTCGACGGCAAGGTGGAATCTAGGCTACGCCATATCACGAAGCTCGCCGCCGTACTGACCTACGGAGCAACCCCATTCCGCGCCTTCGTGGCCGGTAATCCACCGAAGAGGATCGTCAAGCGCGTGCTGCGAGCGCAGATCAATCCACTGCGGCCGGTCACCTTCCTTGCCCATTACGACATGAACAATTGCACGCCTGAAACGCGGGCCCGGTTTCTGGAAAAGGTGCAGATGGCGATGGAACGGTTCTAA
>fig|379.140.peg.2167 NAD(P)H oxidoreductase YRKL (EC 1.6.99.-) @ Putative NADPH-quinone reductase (modulator of drug activity B) @ Flavodoxin 2
ATGAACGTTCTCGTCCTTCATTCGCACCCGGTTGAGGAAAGTTACGGCAAGGCGCTTTACAAACAGACGCTGGATAGCCTTGAGAAAGCCGGCCATGCGGTTGATGCCTGCGATCTCTATGCCGAGAAATTCGACCCCGTGCTCACCCGCCGCGACCGGCTCAGCTATCACGACTATCCCGCCAATTCTGATCTGGTGAAACCCTATGTCGAGCGGCTGAAGCGGGCCGAGGGCCTGGTGCTGGTGACGCCGATCTGGAATTTCGGGTTCCCAGCGATCCTGAAGGGCTATTTCGATCGCGTCTGGCTCCCGGGTGTTTCCTTCGACCTCGTCGACGGCAAGGTGGAATCGCGGCTTCGCCATATCAGGAAGCTCGCCGCCGTTCTGACATACGGCGCCACGCCGTTTCGCGCCTTCGCCGCCGGCAATCCGCCGAAGAAGATTGTCAAACGTGTGCTGAGGGCACAGATCAATCCCCTAAGGCCGGTCACCTTTCTTGCGCATTACGACATGAACAATTGCACCGCGGAAACTCGAGCCAAGTTTCTGGAAAAGGTGAAGACGGCGATGGAGCGGTTCTAG
